.png?width=700&height=241&name=Cell%202025%20Logo%20(Light).png "Cell 2025 Logo (Light)")
Anna Perdrix
Founder & Co-Chief Executive Officer,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Kelly Loyet
Distinguished Scientist,
Genentech
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Philip Beer
Chief Medical Officer,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
President & Founder & Affiliate Professor,
ARNAY Sciences & UMass Chan Medical School
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Aikaterini Gatsiou
Assistant Professor,
Lancaster University
Alain Wagner
Research Director,
Strasbourg University
Alastair Lawson
Vice President,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group Leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Álvaro Enríquez García
Medicinal Chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Anand Kumar
Senior Scientist,
Sanofi
Andreas Reichel
Vice President, Head of Research Pharmacokinetics,
Bayer
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
AgenusBio
Andrew Jamieson
Professor Of Chemical Biology,
University of Glasgow
Andrew Buchanan
Principal Scientist: Biologics Engineering,
AstraZeneca
Andrew Creese
Associate Director,
Immunocore
Andri Vasou
Head of Platform Development,
Bioarchitech
Aneesh Karatt-Vellatt
Co.Founder & Chief Scientific Officer,
Maxion Therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group Leader of PeptLab,
University of Florence
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Antonio Postigo
Chief Scientific Officer,
Stratosvir
Aswin Doekhie
Chief Technology Officer,
EnsiliTech
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
UK Health Security Agency
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of Laboratory,
CEA
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head,
Sanofi
Caleb McClain
Chief Executive Officer,
ANUNA (AI+BIO)
Callum Scott
Head of Development,
Scancell
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Principal Investigator,
Ludwig Institute, Oxford University
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Christian Garde
Director,
Evaxion Biotech
Christopher Scott
Professor,
Queen's University Belfast
Dan Hardy
Chief Executive Officer,
Microsol Science
Daniel Larocque
Innovation Lead, Innovation and Emerging Science,
Sanofi Vaccines
Daniel Fonseca
Senior Research Scientist I ‑ Experimental Immunology,
Immunocore
Daniel Sejer Pedersen
Chemical Development Specialist,
Novo Nordisk A/S
David Craik
Professor,
The University of Queensland
David Brockwell
Professor,
University of Leeds
David Pejoski
Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,
Adoram Therapeutics
David Wraith
Emeritus Professor of Immunology, Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Deniz Eris
Principal Scientist,
Novartis
Dorothy Bray
Senior Executive,
Celtic Biotech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Director Analytical Development & Quality Control,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Elizabeth Boulter
Senior Scientist,
AstraZeneca
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Ernst Weber
Senior Principal Scientist and Bayer Science Fellow,
Bayer AG
Etienne Matous
Head of Lead Optimisation,
Iginnovate
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Roche
Francisca Wollerton
Senior Director,
AstraZeneca
Gabriel Wong
Senior Director Physician, Clinical Research, Immunology,
AstraZeneca
Georgios Skretas
Director,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
Project Manager Immune & Disease Monitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Itishri Sahu
Program Lead Therapeutics,
Ziphius Vaccines
Iulia Oita
CMC Manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jennifer Percival-Alwyn
Scientific Leader,
GSK
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology
Jörg Wischhusen
Professor,
University Hospital Würzburg
.jpg?length=600&name=1048e2c3-e8c7-4b49-9c34-abc9914eac2c-2-11764368speaker_photo-Jutta-Eichler-(2).jpg)
Jutta Eichler
Professor Medicinal Chemistry,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Ken Chow
Health Tech Counsel,
Flanders Investment & Trade
Kerry Chester
Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,
The Antibody Society
Kevin Maskell
Research Director,
Bioarchitech
Knud Jørgen Jensen
Professor,
Copenhagen University
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Lukas Pekar
Lab Head,
Merck
Mads Hald Andersen
Professor,
National Centre For Cancer Immune Therapy (CCIT-dk)
Mani Mudaliar
Director, Quantitative Biomarkers,
Recursion
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
Chief Executive Officer,
ValiRx Plc.
Markus Templin
Head Of Cellular & Molecular Biology,
NMI
Martina Ochs
Project Leader,
CEPI
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Delaney
Principal Scientist,
Novo Nordisk
Mihaela Bozic
Scientist,
T-Therapeutics
Mikhail Kuravskiy
Principal Scientist,
UCB
Nathan Alves
Research Director,
Indiana University School of Medicine
Nesrine Chakroun
Associate Director,
Merus NV
Nicola Ferrari
Director,
AstraZeneca
Norbert Furtmann
Head of AI Innovation NANOBODY® Platform,
Sanofi
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Associate Principal Scientist,
AstraZeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Pawel Stocki
Vice President,
Ossianix
Peter Sondermann
Chief Executive Officer,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist,
Sixfold
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Robert Andrews
Biotech IP Strategist,
Mewburn Ellis LLP
Rodrigo Abreu
Principal Scientist,
LifeArc
Russell LaMontagne
Chief Executive Officer,
Boston Immune Technologies & Therapeutics (BITT)
Sagar Kathuria
Sr. Scientist, Protein Engineering I,
Sanofi
Sandor Batkai
Freelance Consultant,
Batkai.Condulting (ex-Cardior Pharmaceuticals)
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
Roche
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sarah Stuart
High Throughput Characterisation Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Sebastian Sten
Associate Principal Scientist,
AstraZeneca
Sevim Ozgur Bruderle
Lab Head,
Sanofi
Shao-An Xue
Senior Scientist,
University College London
Silvia Crescioli
Business Intelligence Creator,
The Antibody Society
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Simone Friedrich
Director Antibody Discovery & Development,
iOmx Therapeutics
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sonja Merkas
Founder,
Livinovea GmbH
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
NATA
Stefan Zielonka
Senior Director,
Merck KGaA
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell Limited
Thomas Kraft
Principal Scientist,
Roche
Thomas Powell
Senior Scientist,
Immunocore
Timothy Hickling
Immunogenicity Expert Scientist,
Roche
Tomasz Witkos
Associate Director,
AstraZeneca
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trevor Smith
Vice President,
Inovio
Ulrike Rieder
Scientific Lead,
Novartis
Vaios Karanikas
Biomarker Experimental Medicine Leader, Oncology,
Hoffmann La Roche Ltd
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Walter Cabri
Professor,
Fresenius Kabi
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Senior Director - Process Chemistry & CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yiping Wu
Senior Scientist,
AstraZeneca
Zahra Rattray
Senior Lecturer,
University of Strathclyde
Zinaida Dedeic
Senior Scientist,
University of Oxford
Anna Nowocin
Head of Flow Cytometry Standardisation,
MHRA
Charlotte Serra
Vice President, Head of Quality Assurance, Cellular Therapy,
Galapagos
Emma Chan
Director of Process Development,
Orchard Therapeutics
Esther Kitto
VP Clinical Operations,
Resolution-Tx
Ibon Garitaonandia
Chief Scientific Officer,
CellProthera
Kirsty Crame
Vice President,
Medigene
Kyle Zingaro
Head of Gene Therapy Process Sciences,
UCB
Lindsay Davies
Chief Scientific Officer,
NextCell Pharma AB
Muhammad Akram
Senior Medical Director,
Legend Biotech
Rolf Koehler
Associate director,
Novartis
Ruben Rizzi
Senior Vice President Global Regulatory Affairs,
BioNTech SE
Tim Allsopp
Chief Technology Officer,
Laverock Therapeutics
Adam Sidaway
Lead Scientist - Molecular Biology,
Uncommon
Aisling McMahon
Professor of Law,
Maynooth University
Ajan Reginald
Chief Executive Officer,
Roquefort THerapeutics PLC
Akihiro Ko
Chief Executive Officer,
Elixirgen Therapeutics Inc
Alex Smith
Director Regulatory Science,
HoganLovells LLP
Aline Miller
Professor,
University of Manchester
Amir Hefni
Chief Executive Officer,
Resolution Therapeutics
Anton Hutter
Partner, Patent Attorney,
Venner Shipley IP
Athanasios Didangelos
Director, Pharmacology,
Complement Therapeutics Ltd
Benedikt Berninger
Professor,
King's College London
Benjamin Taylor
Senior Director,
AstraZeneca
Catia Andreassi
Director,
AviadoBio
Charlotte Wilding
Patent Attorney,
Venner Shipley
Christopher Middendorf
Senior Director,
Hogan Lovells
Chrysanthi Sitmalidou
Scientist II,
Orchard Therapeutics
Darius Widera
Professor of Stem Cell Biology and Regenerative Medicine,
University of Reading
Darren Nesbeth
Associate Professor,
UCL
Djordje Djordjevic
Co-founder + CEO,
Plurify
Dolores Schendel
Chief Scientific Officer,
Medigene AG
Elena Piletska
Associate Professor in Bioanalytical Chemistry,
University of Leicester
Eleonora Zucchelli
Associate Lead Scientist,
Cell and Gene Therapy Catapult
Eli Gilsohn
VP, Intellectual Property,
Resolution Therapeutics
Emilie Gauthy
Head of CMC,
Zelluna Immunotherapy
Farhad Paylakhi
Co-Founder & Vice President of R&D,
64x Bio
Gabriel Kent
Analytical Development Scientist,
Resolution Therapeutics
Harris Makatsoris
Professor,
King’s College London
Himansu Patel
Head of Quality,
Cell & Gene Therapy Catapult
James Carlson
Principal Safety Director ATMP Enablement,
Roche
Jas Uppal
Founder and CEO,
BQP Consultancy
John Garcia
Head of New Manufacturing Technologies,
UCL
John H Wolfe
Professor,
Child Hosp Philadelphia
Jose Bonafont Arago
Principal Scientist,
danausgt.com
Kirthika Sreenivas
Senior Scientist,
Polpharma Biologics
Klara Kulenkampff
Project Manager,
Bayer
Leila Abbas
PreClinical Manager,
Rinri Therapeutics
Lucy Williams
Partner,
J A Kemp LLP
Lucy Barnes
Patent Attorney,
J A Kemp
Luis Ayala
Scientist Perfusion Systems,
Merck KGaA
Luz Alonso-Crisostomo
Senior Scientist,
AstraZeneca
Mahdieh Hassanjani
Innovation Project Manager,
Cell and Gene Therapy Catapult
Manuel Carrondo
senior vp,
IBET
Marc Schneider
Director Product Supply,
BioNTech SE
Marcel van Houten
Director Global Supply Chain,
Orchard Therapeutics Ltd
Maria Luisa Giorello
Global Gene Therapy Platform Enablement Director,
Pfizer Ltd
Marina Tarunina
Research Director,
Plasticell Ltd
Martin Dass
Scientist,
Boehringer Ingelheim Pharma GmbH & Co. KG
Matthew Gibson
Professor,
University of Manchester
Matthew Garner
Head of Intellectual Property,
Catapult
Menasheh Fogel
IT Head, Cell and Gene Therapy,
Bayer
Millie Fox
Senior Scientist,
AstraZeneca
Molly Stevens
John Black Professor of Bionanoscience,
University of Oxford
Monica Raimo
Sr. R&D Manager,
Glycostem Therapeutics
Nabiha Saklayen
CEO & Co-Founder,
Cellino
-1.webp?length=600&name=main-qimg-6c062adcbace942e5c2a2ea3ec7caf5a%20(1)-1.webp)
Nicolas Weber
Quality Team Leader QC,
Novartis Pharma
Nirai Govindasamy
Senior Scientist,
Bluu Seafood
Nitin Garg
Director, CMC product lead,
Adaptimmune
-(1).jpg?length=600&name=1a6e8ff6-fbaf-4022-930b-2a8a8a957239-2-11764368speaker_photo-Patricia-Mendoza-8961-(1)-(1).jpg)
Patricia Mendoza
Senior Scientist,
AstraZeneca
Patrizia Ferretti
Professor of Regenerative Biology,
University College London
Philippe Henon
Chairman,
CellProthera SAS
Rahul Khetan
Venture Capital Associate,
UCB Ventures
Raiko Stephan
Gene and Cell Therapy Lead,
Novartis
Roelof Rongen
Chief Executive Officer,
Adolore BioTherapeutics
Roshni Desai
Nonclinical Assessor,
MHRA
Sakis Mantalaris
Professor,
Trinity College Dublin & NIBRT
Sally Gu
Senior Associate,
Hogan Lovells
Sam Goldsmith
Head of Commercialisation of Research & Investments,
CGT Catapult
Sarah Howlett
Associate Director,
AstraZeneca
Sergey Piletsky
Professor in Bioanalytical Chemistry,
University of Leicester
Simon Chandler
Chief Executive Officer,
Rinri Therapeutics
Stephen Sullivan
Chief Operating Officer,
iPSirius
Sujith Sebastian
Viral Vector Hub Manager,
NHSBT
Terri Gaskell
Chief Technology Officer,
Rinri Therapeutics
Ulrich Rümenapp
Senior Biotech Program Lead,
Bayer AG
Uwe Buecheler
Senior Advisor - Biopharmaceuicals,
Boehringer Ingelheim
Vicki Coutinho
Managing Director,
Geni Consulting
Volker Huppert
Chief Development Officer,
Glycostem Therapeutics B.V.
Xavier Fontana
Principal Scientist,
Adaptimmune
Sponsors of Cell 2024 Included
Gold Sponsors
Asimov
Gold Sponsor
Asimov is developing a synthetic biology platform – from cells to software – to enable better design and manufacture of next-generation therapeutics. Asimov’s CHO Edge System for biologic production minimizes the risk of cell line development by enabling exploration of vector design space – Asimov routinely achieves titers of 7–11 g/L across modalities. Asimov is applying the same approach to improve cell & gene therapies – by developing stable lentiviral cell lines and a best-in-class AAV expression system, and enhancing safety profiles through the creation of synthetic tissue specific promoters. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com
Novo Nordisk Pharmatech A/S
Gold Sponsor
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of ingredients for the biopharmaceutical and pharmaceutical industries. The company specializes in the cGMP-manufacturing of Recombinant Insulin, Superior Enzymes, and Benzalkonium Chloride (BKC). Recombinant Insulin is a versatile ingredient for the manufacturing of a broad range of different therapeutic therapies, from monoclonal antibodies to cell and gene therapies and vaccines, and is approved by regulatory bodies worldwide, including FDA and EMA.
Thermo Fisher Scientific
Gold Sponsor
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. PPD, part of Thermo Fisher Scientific, provides clinical drug development and analytical services that enhance customer innovation and productivity. Utilizing patient-centered strategies and data analytics, we cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites and comprehensive laboratory services. Thermo Fisher is a trusted partner for every step in the drug development journey with unrivalled quality, reliability and expertise. For more information about Thermo Fisher Scientific, please visit www.thermofisher.com
Silver Sponsors
Advanced Instruments
Silver Sponsor
Advanced Instruments is a global provider of scientific and analytical solutions for the biopharma and clinical industries. Our company’s innovations have helped organizations improve quality, achieve reliable outcomes, and increase productivity for more than 70 years. Our focus on service, quality, and reliability has made us a leading developer and manufacturer of analytical instruments and services for the biopharmaceutical, clinical, and food & beverage industries. Our newest addition, the Artel portfolio, includes leading analytical instruments, software and services that validate, automate, and calibrate critical liquid handling processes and instrumentation. Our Solentim portfolio delivers best-in-class imaging and single-cell deposition technologies for cell line development workflows. And our OsmoTECH® and OsmoPRO® micro-osmometers support the workflows that labs worldwide rely on for the delivery of accurate and timely results. www.aicompanies.com
GemPharmatech
Silver Sponsor
GemPharmatech is a leading contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. Our company is steadfast in its commitment to providing cutting-edge and novel solutions to researchers in their pursuit of scientific exploration and pharmaceutical development. At GemPharmatech, we specialize in the development of animal models utilizing advanced gene-editing technologies, and we have an extensive library of KO/cKO mice, humanized mice, immunodeficient mice, and germ-free mice. We offer a wide range of preclinical services, including mouse model customization, pharmacology services such as drug efficacy evaluation and mouse phenotyping, gene editing, cryopreservation, and customized breeding. Our ultimate goal is to accelerate scientific advancement and pharmaceutical development by supporting our clients with the most innovative tools and services. We have amassed one of the broadest collections of mouse models in the world, which have garnered immense popularity among scientists globally. By partnering with GemPharmatech, our clients benefit from having access to a comprehensive range of research tools and services to aid them in their research endeavors and promote scientific discovery. GemPharmatech is committed to pushing the boundaries of preclinical research and assisting our customers in achieving their research ambitions. We take great pride in providing exceptional customer service and are dedicated to providing our clients with the highest-quality research solutions.
GenScript UK Ltd
Silver Sponsor
GenScript Biotech Corporation is a world leading technology and service provider of life science R&D and manufacturing, founded in 2002 as one of the first commercialise gene synthesis providers. GenScript provides life sciences services and products to scientists in over 200 countries worldwide, including gene and gene fragments synthesis, DNA/RNA/NGS/qPRC/tRNA, & siRNA oligos, mRNA & circular RNA synthesis, custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology, as well as a variety of other research-focused catalogue products. After two decades of rapid growth, the company has expanded its business in recent years into the fields of immunotherapy and early-phase drug discovery services, CDMO and microbiology. Driven by the corporate mission of “make people and nature healthier through biotechnology”, GenScript strives to become the most trustworthy biotech company in the world. GenScript offers global support for its loyal customers with dedicated sites in the Netherlands and the UK and a strong global remote workforce.
iotaSciences
Silver Sponsor
iotaSciences provides instrumentation to facilitate and simplify applications that require single-cell isolation, such as cell line development, genome editing and omics-based analyses. Using automated fluid handling, our single-cell isolation technology streamlines your experiments without the need for complex protocols and excessive manual handling. Our portfolio of scientific instruments deliver powerful automation, high single-cell isolation efficiency and viability, as well as documented proof of single-cell isolation with image-capture capabilities. We additionally operate an efficient and streamlined genome-editing pipeline for iPSCs and provide professional services for bespoke genome editing projects, combining our expertise in both CRISPR-Cas technologies and single-cell isolation.
Kuhner Shaker
Silver Sponsor
Kuhner Shaker design, manufacture and supply robust shaking incubators. Kuhner Shaker can also provide bioreactors at 10L, 50L, 200L, and 2,500L scale for pre-production and production. The bioreactors use the same orbital motion as the shaking incubators which helps predicting hydrodynamics during scale up. Both the shaking incubators and the orbital bioreactors can be used for research but they have also been designed to fully support use in GMP/Cleanroom environments.
QIAGEN GmbH
Silver Sponsor
QIAGEN pushes the boundaries of innovation to improve our understanding of DNA, RNA and proteins – the building blocks of life. We enable our customers to unlock valuable insights from any biological sample – be it blood, a throat swab or many other materials. Our products serve a wide range of applications, including cell and gene therapy. In this space, customers can find solutions for precise determination of plasmid quality, viral titer, vector copy number and robust contaminant testing. Our reputation is based on confidence in decisions, clarity of results and pride in the insights our customers achieve. More than 35 Nobel Prize winners among more than 500,000 customers worldwide are proof of that success. Together, we are making improvements in life possible. Discover more at http://www.qiagen.com.
Sartorius Lab Instruments GmbH & Co. KG
Silver Sponsor
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe.
Bronze Sponsors
Aseptic Technologies
Bronze Sponsor
Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products. The AT-Closed Vial® Technology is an innovative vial, closed before filling, made out of polymer materials. Together with our Filling Lines, the technology allows for contamination risk reduction and higher levels of sterility. In addition, its exceptional features make the AT-Closed Vial® able to maintain Container Closure Integrity (CCI) at cryogenic temperatures (down to -196°C). As a member of SKAN Group, we leverage the technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally. Furthermore, we share decades of expertise in injection molding and manufacturing in cleanroom, offering customized ready-to-use assemblies for pharmaceutical processes. www.aseptictech.com www.skan.com
Axion Biosystems, INC
Bronze Sponsor
Axion BioSystems is a leading life science tools company focused on innovative in vitro live-cell assays to study the function of cells for drug discovery, disease modeling, cancer immunotherapy, safety/toxicity, and more. Monitor intricate, neural network activity with a noninvasive, easy-to-use assay on the world’s most advanced microelectrode array (MEA) system, the Maestro. With the Omni, the next generation in kinetic live-cell imaging, generate high-quality time-lapse imaging, combining fast, compact imaging hardware with powerful image analysis algorithms. At Axion BioSystems, our goal is to help you capture the biology of your cells.
Beckman Coulter
Bronze Sponsor
With a relentless mission to empower those seeking answers to life’s important scientific questions, Beckman Coulter Life Sciences is a preferred laboratory partner providing automation and innovation solutions for Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling workflows. With a legacy dating back to 1935, our technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable pioneering discoveries. Beckman Coulter Life Sciences is headquartered in Indianapolis, Indiana with 11 operational hubs around the world and employs more than 3,300 associates with more than 300,000 systems installed globally.
.png?length=600&name=55b8d348-c564-4ef9-ba33-f793f95a3c62-2-5668375logo-bm-logo-circle-rgb-(1).png){kind=logo}
BioMerieux UK Limited
Bronze Sponsor
To protect patients, provide safe products and minimise vein to vein time, cellular therapies sites need state-of-the-art quality control solutions. bioMérieux’s portfolio of microbiology testing solutions enable sites to perform testing at each stage of production. bioMérieux solutions are adapted for the unique set of requirements for testing C> products. Helping to maintain regulatory compliance and optimise operations for the future. BACT/ALERT 3D DUAL T: Compendial, rapid and automated sterility testing. BIOFIRE MYCOPLASMA: Results in 1 hour test ENDOZYME II GO: LAL-free endotoxin test, just add water and your sample 3P Solutions: for environmental monitoring, 3P SMART plates, 3P Connect and 3P Enterprise bioMérieux industrial microbiology (biomerieux-industry.com)
CancerTools
Bronze Sponsor
CancerTools.org - Global Research Collaborative: CancerTools.org is a unique global, non-profit cancer research tools biorepository. As part of Cancer Research UK, we are determined to accelerate cancer discoveries by funding research. Our repository features novel research tools from 180 leading academic universities and cancer centres across the globe, with a unique collection of cancer-relevant reagents for research breakthroughs. Cancer Cell Lines & Research Tools Portfolio: Our portfolio covers an extensive range of validated cell lines, organoids, mouse and PDX models and more - tailored and specialised by cancer research area. Exemplary support for researchers: We provide comprehensive support to academic researchers and industry partners globally, ensuring access to high-quality cancer research tools. Our efficient in-bound shipping, storage, production, maintenance, and worldwide distribution guarantee you are always equipped with the research materials you need.
Eppendorf
Bronze Sponsor
We Help Bring Life-Saving Treatments to the World Large cell numbers are needed for the development of cell therapies and stem cell-based drug research applications. By utilizing its strong synergies in cell culture expertise, bioreactor technology, and polymer manufacturing, Eppendorf has emerged as an expert partner for the cultivation of (stem-) cells at large scale. With our equipment, training programs, and application services, we support scientists in resolving cultivation bottlenecks during the development of cell-based applications from basic research to cell and gene therapy applications. The need for advanced solutions is increasing. With our expertise, we help to stimulate the growth of your cultures and cultivate solutions tailored to your challenges. Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5,000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
Hamilton Company
Bronze Sponsor
Hamilton process sensors are well known for high quality, long life, unique features, and competitive pricing. In order to meet these rigorous requirements, we are constantly striving to find new ways to design our sensors. As a result of the extensive work by our research and development department, Hamilton is able to offer outstanding solutions for pH, dissolved oxygen, dissolved carbon dioxide, cell density, conductivity and ORP monitoring.
Sartorius BIA Separations
Bronze Sponsor
Sartorius BIA Separations develops and manufactures market-leading CIM® monolithic chromatographic columns for the purification and analysis of large biomolecules, such as viruses, plasmids, and mRNA, which are applied in cell and gene therapies. The company’s Cornerstone® Biomanufacturing Development Services are the result of more than 25 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production while improving the safety of therapeutic products. Sartorius BIA's technology for manufacturing-scale purification is already used in the production of the first commercialized advanced therapeutics;the company also has a keen presence with novel drug candidates in the clinical pipeline.
Sphere Fluidics
Bronze Sponsor
Sphere Fluidics is the Cambridge (UK)-based microfluidics tools company with a range of novel cell encapsulation products for single-cell analysis and isolation. The Sphere Fluidics proprietary picodroplet microfluidic technology platform is designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a droplet while maintaining viability. Flagship product Cyto-Mine® provides an integrated system with the ability to select, manipulate, analyze, and isolate cells, through an easy to use and intuitive interface that can automatically screen up to 40 million cells in a matter of hours. This unrivaled throughput aids in the acceleration of biopharmaceutical discovery and development, cell therapy, and synthetic biology workflows, easing the journey of discovery in labs globally.
Waters UK Limited
Bronze Sponsor
Waters Corporation is a global leader in analytical instruments and software, providing innovative solutions for the biopharmaceutical industry. With decades of experience, Waters supports the development and manufacturing of biopharmaceuticals, ensuring high-quality, safe, and effective therapies.
Network & Programme Sponsors
Air Products
Network & Programme Sponsor
Air Products (NYSE:APD) is a world-leading industrial gases company in operation for over 80 years focused on serving energy, environmental, and emerging markets. The Company has two growth pillars driven by sustainability. Air Products’ base business provides essential industrial gases, related equipment and applications expertise to customers in dozens of industries, including refining, chemicals, metals, electronics, manufacturing, and food. The Company also develops, engineers, builds, owns and operates some of the world's largest clean hydrogen projects supporting the transition to low- and zero-carbon energy in the heavy-duty transportation and industrial sectors. Additionally, Air Products is the world leader in the supply of liquefied natural gas process technology and equipment, and provides turbomachinery, membrane systems and cryogenic containers globally. The Company had fiscal 2023 sales of $12.6 billion from operations in approximately 50 countries and has a current market capitalisation of about $50 billion. Approximately 23,000 passionate, talented and committed employees from diverse backgrounds are driven by Air Products’ higher purpose to create innovative solutions that benefit the environment, enhance sustainability and reimagine what's possible to address the challenges facing customers, communities, and the world. For more information, visit www.airproducts.co.uk or follow us on LinkedIn, X, Facebook or Instagram.
CELLforCURE by SEQENS
Network & Programme Sponsor
CELLforCURE by SEQENS is currently one of the very few CDMOs worldwide experienced with the manufacturing of commercial cell therapy drugs. With more than 10 000 m2 of building surface and a 2200 m2 GMP area made of 6 independent GMP lines, located close to Paris, CELLforCURE is a “One Stop Shop” CDMO for ATMP development and manufacturing across a large range of cell types. CELLforCure has a 10-year track record in the development and commercial manufacture of C&G therapies.
Cellin Technologies
Network & Programme Sponsor
Cellin Technologies, established in 2013, pioneered the regenerative medicine arena in North of Europe by specializing in the analysis, design, and production of cell therapy products. We are here to develop proprietary technologies for experimental or clinical applications on lab- and commercial-scale.
Cojourney
Network & Programme Sponsor
CoJourney offers an exceptional CDMO experience, specializing in process development and cGMP manufacturing of Plasmids, Viral Vectors, and mRNA. Highlights: Guranteed Yields for Plasmids and AAV Cost leaders in the CDMO industry Research Grade and GMP grade Plasmids, Viral Vectors, and mRNA Our manufacturing platforms have earned the trust of over 40 satisfied gene therapy customers. We are your trusted guide on the Gene Therapy journey, with Plasmids available in 4 months (from development to GMP release) and mRNA in 5 months (from plasmids development to GMP release).
Haier Biomedical
Network & Programme Sponsor
Haier Biomedical leads biotechnological innovation, offering cutting-edge solutions for the Life Science sector. We design and manufacture comprehensive cold storage solutions for biological sample banks, blood safety, vaccine storage, and medical supplies. Beyond storage, we provide advanced laboratory equipment such as incubators, centrifuges, climate chambers, safety cabinets, and wireless asset monitoring for real-time temperature and status tracking. Our expert service support team offers planned preventative maintenance, rapid breakdown assistance, and customised service contracts. Additional services include calibrations, temperature mapping, and IQ/OQ/PQ certifications, ensuring your laboratory equipment is maintained to the highest standards. We are here to elevate your laboratory experience through innovation and service excellence.
HistologiX
Network & Programme Sponsor
HistologiX is a trusted GLP & GCP compliant CRO for tissue-based analysis - make the most of our expertise. We help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Working collaboratively, our experienced scientific team provides a bespoke service allowing you to make the most of our expertise in histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), In Situ Hybridisation (ISH) using RNAScope & cutting-edge digital image analysis using Visiopharm. For each project, our experienced scientists work as an extension of your in-house team to define your bespoke project requirements and customise the study plan to ensure you get the results you need. We provide an excellent quality technical service supporting biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses, therapeutic antibodies, small molecules, and RNA modifying enzymes. www.histologix.com
.png?length=600&name=2fa02335-fcdb-40f0-b4d1-249858accff7-2-5668375logo-InVitria-Performance-Defined-Logo-8-(1).png){kind=logo}
.jpg?length=600&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Nanion Technologies
Network & Programme Sponsor
Nanion Technologies is a global leading life sciences tools company combining since more than 20 years exceptional instrumentation with trusted scientific support, to accelerate successful drug development and scientific discoveries. As a leading provider of automated patch clamp systems with a wide range of throughput capabilities and formats, we have expanded our product range to in vitro systems for membrane pump/transporter, bilayer recordings, contractility and cell analytics measurements. From studying the biophysical properties and pharmacological profile of ion channels and transporters in native and reconstituted membranes to understanding the effect of their modulation on cell survival and function, our state-of-the-art instrumentation has revolutionized drug discovery, lead optimisation and safety assessment. Now, with our newest technology, AtlaZ, we introduce high-throughput impedance spectroscopy, allowing simultaneous, label-free and time resolved monitoring of diverse cellular responses. With the capability to track live cells in scalable throughput (6x 96-well plate configuration), AtlaZ operates across a range of frequencies (0.1 KHz – 100 KHz), unveiling nuanced information about cell confluence, proliferation and cytotoxicity, cancer immunotherapy as well as formation of tight junctions in epithelial and endothelial cell lines. Our user-oriented interface providing real-time and automated data analysis, offers simplicity you will love. Applications include: Cell Proliferation, Cytotoxicity, Immune Cell-Mediated Cytotoxicity, Cancer Immunotherapy, Immuno-Oncology, Oncolytic Viruses, Receptor-mediated Signalling.
Nova Biomedical
Network & Programme Sponsor
Nova Biomedical manufacture a series of BioProfile® automated chemistry and cell analysis analysers for rapid testing of key nutrients, metabolites, gases, and cell status in cell culture and fermentation media. BioProfile FLEX2 combines Nova’s groundbreaking MicroSensor™ Card technology with optical measurement and freezing point osmometry for an automated and comprehensive cell culture analyser that eliminates chemistry sensor maintenance, increases analyser speed, and reduces sample volume. The full 16 cell culture test menu includes: Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, PCO2, PO2, total cell density, viable cell density, viability, cell diameter, and osmolality. BioProfile FLEX2 is capable of automated online sampling, to Ambr® 15 and 250 microbioreactors, and to bench scale bioreactor systems. BioProfile FAST CDV is a fully automated analyser designed to meet the needs of cell culture scientists requiring high throughput, rapid and extremely accurate cell density and cell viability measurements. Utilising trypan blue dye exclusion methodology with the industry’s most innovative and automated sampling preparation, results are available in just one minute while eliminating virtually all manual sample prep procedures. For more information visit https://www.novabiomedical.com/
OXB
Network & Programme Sponsor
OXB is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors;the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
OXGENE, a WuXi Advanced therapies Company
Network & Programme Sponsor
OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, develops pioneering technologies to accelerate the discovery and biomanufacture of cell and gene therapies. OXGENE provides expert design and engineering services for viral vector optimisation and cell line development as a developing innovative new technology to transform the manufacture of cell and gene therapies. Our biomanufacturing solutions further accelerate the development and scalable manufacture of lentiviral, AAV or adenoviral vector-based therapeutics.
Pathoquest
Network & Programme Sponsor
PathoQuest is a global CRO that specializes in biologics GMP quality testing based on next-generation sequencing (NGS) for viral safety and genetic characterization. The company’s proprietary NGS-based testing approach delivers actionable Quality Control reports to the biopharmaceutical industry for cell & gene therapy, vaccines and recombinants. Faster, safer, Animal Free.
PeptiGrowth
Network & Programme Sponsor
PeptiGrowth Inc., a subsidiary of Mitsubishi Corporation and PeptiDream, offers innovative synthetic peptides that deliver equivalent or superior activity compared to recombinant growth factors and cytokines. These peptides, known as "Synthetic Peptide Growth Factors" or PG-peptides, are chemically synthesized, eliminating lot-to-lot variability and the risk of contamination from animal-derived components. This makes them ideal for applications in stem cell research, cell therapy, and regenerative medicine. PG-peptides exhibit superior stability under storage and culturing conditions compared to conventional growth factors and cytokines. Our product lineup includes synthetic peptide growth factors for HGF, BDNF, Noggin, VEGF, Wnt3a, TPO, and the latest product, FGF2 launched in October 2024. By delivering high-quality synthetic peptide growth factors, PeptiGrowth is committed to advancing the development and realization of stem cell research, cell therapy, and regenerative medicine.
Reading Scientific Services Ltd
Network & Programme Sponsor
RSSL, the largest independent laboratory in the UK with over 300 scientists, expanded its capabilities in November 2023 by opening a fourth 26,000 sq. ft. facility. This new space enables RSSL to provide a comprehensive range of services supporting biotherapeutic companies and CDMOs. Key offerings include cell potency bioassays, with dedicated culture suites for banking, transfection, and bioassay;flow cytometry;and specialist LC-MS services for viral vectors, proteins, and mRNA therapeutics. Additional services encompass product characterisation to ICHQ6B standards, safety testing, method development and validation, environmental monitoring, QP & GMP training, and GMP-compliant labs for materials QC release testing and contamination investigations.
RoslinCT
Network & Programme Sponsor
RoslinCT is a global CDMO focused on Advanced Cell and Gene Therapies. It was established in 2006, built upon the groundbreaking cloning technology of Dolly the Sheep. RoslinCT is one of the first to produce clinical-grade human pluripotent stem cells and developed the first CRISPR-based therapy for the treatment of sickle cell disease and beta thalassemia, taking it from early development to commercialization. With 22 cGMP cell therapy processing suites in Scotland and Massachusetts, RoslinCT provides innovative PD/AD, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, cell banking and differentiation.
SGS Vitrology
Network & Programme Sponsor
SSG Vitrology Limited was founded in 2007 and acquired by SGS in May 2012. The site provides safety testing services of biologics, with a strong focus on quality of service and scientific ability. Our team of experienced scientists have over 20+ years experience providing a comprehensive range of GMP, FDA, EP, ICH compliant validated assays. As a world leader in biopharmaceutical testing services, SGS Vitrology offer you a complete range of GLP/GMP biologics safety testing, including virology, cellular and molecular biology, as well as microbiology and electron microscopy. We pay special attention to our customers’ turnaround time requirements and partner that with best in class customer service and communication. As a result, we help you to ensure product safety and meet your regulatory requirements, therefore adding value to your business by providing reliability, high quality & compliant GMP validated assays, scientific expertise, and pro-active communication with direct access to your dedicated project management team and scientists. SGS Vitrology has decades of experience characterizing cell banks and virus seeds used in the manufacture of gene therapy vectors, vaccines, and recombinant proteins. We have worked with clients using a range of cell lines (e.g. CHO, HEK293, Sp2/0, Hi5, Sf9, MDCK, Hybridoma) and viral vectors (e.g. Adeno, AAV, Lentivirus, Vaccinia). A summary of our services are as follows: • Cell Bank and Virus Seed Characterisation per the major compendia, regulatory and ICH guidelines • Raw material and Bulk Harvest testing • Drug Substance and Final Product testing • Custom Development/Validation of assays including new or method transfers
Stilla Technologies
Network & Programme Sponsor
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the Nio™ system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA.
SYNENTEC
Network & Programme Sponsor
SYNENTEC is a leading manufacturer of high-throughput fluorescence and brightfield cell imaging systems & automation peripherals for cell line development, upstream applications, drug discovery, cancer research, immunology, stem cell research and cell-based assays. The NYONE and CELLAVISTA imaging systems have proven integration capabilities into automated cell culture workstations and contribute to shortening timelines in research with their high throughput imaging capabilities at high resolution. SYNENTEC uses powerful image processing algorithms to give researchers the results they need to answer their questions on a single cell level.
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Novotel London West
1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR
Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.
By Air
London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.
London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.
By Underground & Bus
Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.
For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.
By Rail
The closest National Rail train station is Kensington Olympia (20 minutes walk).
By Car
Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.
Parking
Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml
Oxford Global has secured a number of bedrooms at the Novotel London West at a reduced conference rate:
- Monday 10th November 2025 – £170, breakfast included (VAT added at checkout)
- Tuesday 11th November 2025 – £170, breakfast included (VAT added at checkout)
*Please note: £15 supplement is applicable for double occupancy
The final cut-off date to book bedrooms is Friday 17th October 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.
Should you wish to book a room, please click here
Additionally, we kindly remind all attendees to only book their accommodation if they are registered for the event. This ensures that accommodations are available for those who have officially secured their attendance.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Cell 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
